Traneta M2.5 mg+850 mg

Traneta M 2.5 mg+850 mg is a fixed-dose combination antidiabetic medicine used as an adjunct to diet and regular exercise to improve glycemic (blood sugar) control in adults with type 2 diabetes mellitus. It is prescribed when treatment with both Linagliptin and Metformin Hydrochloride is considered clinically appropriate for the patient.

This combination is commonly used in patients who have inadequate blood sugar control on Metformin alone, or who require the complementary mechanisms of a DPP-4 inhibitor and a biguanide to achieve their target HbA1c. Combining both agents in a single tablet also helps simplify the dosing regimen and improve treatment adherence.

It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Combination Oral Hypoglycemic Preparation (DPP-4 inhibitor + Biguanide)

This combination brings together two antidiabetic agents with complementary, non-overlapping mechanisms of action, allowing for improved glycemic control through both incretin-based and insulin-sensitizing pathways.

Linagliptin

Linagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor. DPP-4 is the enzyme responsible for breaking down the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By inhibiting DPP-4, Linagliptin raises the circulating levels of active incretin hormones. This in turn stimulates glucose-dependent insulin release from pancreatic beta (β) cells and suppresses excess glucagon secretion from pancreatic alpha (α) cells, helping to lower both fasting and post-meal blood glucose without a high inherent risk of hypoglycemia.

Metformin Hydrochloride

Metformin Hydrochloride is a biguanide-class oral antihyperglycemic agent. Unlike sulfonylureas, it does not stimulate insulin secretion and therefore does not typically cause hypoglycemia on its own. Metformin lowers both basal and postprandial plasma glucose primarily by:

• Decreasing hepatic glucose production (gluconeogenesis)
• Reducing intestinal absorption of glucose
• Improving insulin sensitivity and increasing peripheral glucose uptake and utilization

Together, Linagliptin and Metformin Hydrochloride act on different aspects of glucose metabolism, providing an additive glucose-lowering effect for patients with type 2 diabetes.

Traneta M 2.5 mg+850 mg may interact with several classes of medicines. Inform your doctor about all prescription, over-the-counter, and herbal products you are taking before starting this combination.

Alcohol consumption should also be limited, as it can potentiate Metformin's effect on lactic acid metabolism and increase the risk of hypoglycemia.

Most patients tolerate this combination well. The most commonly reported side effects are:

• Nasopharyngitis (common cold–like symptoms)
• Diarrhea and other mild gastrointestinal disturbances

Hypoglycemia (low blood sugar) is more frequently observed when this combination is used together with a sulfonylurea. Less commonly, patients may experience nausea, vomiting, abdominal discomfort, headache, or a metallic taste, particularly during dose escalation. Report any severe or persistent symptoms to your doctor promptly.

There are no adequate and well-controlled studies of this combination, or its individual components, in pregnant women. It should therefore be used during pregnancy only if clearly needed and under direct medical supervision. In general, insulin is often preferred to maintain glycemic control during pregnancy.

Caution should also be exercised when this combination is administered to a breastfeeding mother, as it is not known whether Linagliptin passes into human breast milk, while Metformin is known to be excreted in small amounts. Consult a physician before use while breastfeeding.

If a patient taking Metformin develops lactic acidosis, the drug should be discontinued immediately and supportive treatment started without delay. There have been postmarketing reports of acute pancreatitis associated with Linagliptin; if pancreatitis is suspected, this combination should be stopped promptly.

Treatment should be temporarily discontinued in patients undergoing radiologic studies involving intravascular iodinated contrast media, or before any surgical procedure requiring restricted food and fluid intake, and resumed only after kidney function is confirmed to be normal. Long-term Metformin use may lower vitamin B12 levels, so periodic hematologic monitoring is advised.

Lactic Acidosis

Lactic acidosis is a rare but serious complication of Metformin therapy. It typically occurs alongside other severe health conditions, such as heart attack or kidney failure. Warning signs include abdominal discomfort, reduced appetite, diarrhea, rapid or shallow breathing, muscle pain or cramping, and unusual tiredness or weakness. Seek medical attention immediately if these symptoms occur. Adequate fluid intake should be maintained during exercise, illness, vomiting, or diarrhea.

General Precautions

• Alcohol: Drinking alcohol may cause severe low blood sugar and increase lactic acidosis risk.
• Other medicines: Be cautious with nonprescription drugs such as aspirin and medicines for appetite control, asthma, colds, cough, or sinus problems.
• Family awareness: Family members should know how to recognize and respond to hypoglycemia.
• Travel: Carry a recent prescription and medical history; adjust meal timing carefully across time zones.
• Emergency preparedness: Wear a diabetes medical ID and carry a card listing current medicines at all times.

Hypoglycemia Risk

Hypoglycemia may occur due to delayed or missed meals, alcohol use, excessive exercise, inability to eat due to nausea or vomiting, or combination with other diabetes medicines. Learn to recognize your personal symptoms of low blood sugar and treat them promptly to avoid loss of consciousness.

In case of overdose, standard supportive measures should be employed, including removal of unabsorbed drug from the gastrointestinal tract, clinical monitoring, and supportive treatment as needed. Linagliptin is unlikely to be significantly removed by hemodialysis or peritoneal dialysis, whereas Metformin Hydrochloride is dialyzable.

In clinical trials, single doses of Linagliptin up to 600 mg (about 120 times the recommended daily dose) did not produce dose-related adverse reactions in healthy subjects. For Metformin, overdose has been reported with ingestion of more than 50 grams; hypoglycemia occurred in around 10% of cases, and lactic acidosis was reported in approximately 32% of Metformin overdose cases. Seek emergency medical care immediately in case of suspected overdose.

• Store in a cool and dry place, below 30°C
• Protect from light and moisture
• Keep out of the reach of children

Renal Impairment

Contraindicated in patients with renal impairment, given the risk of Metformin accumulation and lactic acidosis. Kidney function should be assessed before starting therapy and monitored periodically thereafter.

Hepatic Impairment

Should be used with caution in patients with hepatic impairment, as liver disease is associated with a higher risk of lactic acidosis with Metformin therapy.

Elderly Patients

Elderly patients are more likely to have age-related decline in renal function; dose selection should be conservative, and kidney function should be monitored more frequently.

Pediatric Use

Safety and effectiveness of this combination have not been established in patients below 18 years of age; it is not recommended for pediatric use.